Skip to main content

Table 3 Treatment compliance

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of cycles (%)

 

DD/DI arm

HDI arm

N° cycles delivered

272

701

According to protocol

72

(26)

187

(27)

Modified in dose less than 20%

64

(23)

176

(25)

Modified in dose more than 20%

136

(50)

338

(48)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us